NASDAQ:TCMD

Tactile Systems Technology Competitors

$56.40
+1.14 (+2.06 %)
(As of 04/14/2021 12:32 PM ET)
Add
Compare
Today's Range
$56.32
Now: $56.40
$56.40
50-Day Range
$47.66
MA: $51.97
$59.77
52-Week Range
$30.31
Now: $56.40
$64.53
Volume205 shs
Average Volume167,317 shs
Market Capitalization$1.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.69

Competitors

Tactile Systems Technology (NASDAQ:TCMD) Vs. GKOS, CMD, NUVA, MMSI, ATRC, and IRTC

Should you be buying TCMD stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Tactile Systems Technology, including Glaukos (GKOS), Cantel Medical (CMD), NuVasive (NUVA), Merit Medical Systems (MMSI), AtriCure (ATRC), and iRhythm Technologies (IRTC).

Tactile Systems Technology (NASDAQ:TCMD) and Glaukos (NYSE:GKOS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Tactile Systems Technology and Glaukos' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tactile Systems Technology-4.57%1.37%0.99%
Glaukos-33.61%-7.99%-5.87%

Analyst Ratings

This is a summary of recent recommendations and price targets for Tactile Systems Technology and Glaukos, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tactile Systems Technology01202.67
Glaukos16102.00

Tactile Systems Technology presently has a consensus price target of $59.00, indicating a potential upside of 4.76%. Glaukos has a consensus price target of $66.3750, indicating a potential downside of 21.44%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, equities analysts clearly believe Tactile Systems Technology is more favorable than Glaukos.

Risk and Volatility

Tactile Systems Technology has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, Glaukos has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500.

Earnings & Valuation

This table compares Tactile Systems Technology and Glaukos' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tactile Systems Technology$189.49 million5.84$10.97 million$0.56100.71
Glaukos$236.98 million16.40$15.42 million($0.10)-848.80

Glaukos has higher revenue and earnings than Tactile Systems Technology. Glaukos is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Tactile Systems Technology beats Glaukos on 7 of the 12 factors compared between the two stocks.

Tactile Systems Technology (NASDAQ:TCMD) and Cantel Medical (NYSE:CMD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Profitability

This table compares Tactile Systems Technology and Cantel Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tactile Systems Technology-4.57%1.37%0.99%
Cantel Medical3.38%11.19%4.10%

Analyst Ratings

This is a summary of recent recommendations and price targets for Tactile Systems Technology and Cantel Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tactile Systems Technology01202.67
Cantel Medical12102.00

Tactile Systems Technology presently has a consensus price target of $59.00, indicating a potential upside of 4.76%. Cantel Medical has a consensus price target of $71.50, indicating a potential downside of 16.22%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, equities analysts clearly believe Tactile Systems Technology is more favorable than Cantel Medical.

Insider and Institutional Ownership

95.0% of Cantel Medical shares are owned by institutional investors. 5.3% of Tactile Systems Technology shares are owned by company insiders. Comparatively, 10.7% of Cantel Medical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Tactile Systems Technology has a beta of 1.69, meaning that its stock price is 69% more volatile than the S&P 500. Comparatively, Cantel Medical has a beta of 1.54, meaning that its stock price is 54% more volatile than the S&P 500.

Earnings & Valuation

This table compares Tactile Systems Technology and Cantel Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tactile Systems Technology$189.49 million5.84$10.97 million$0.56100.71
Cantel Medical$1.02 billion3.55$13.71 million$1.6551.75

Cantel Medical has higher revenue and earnings than Tactile Systems Technology. Cantel Medical is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Summary

Cantel Medical beats Tactile Systems Technology on 9 of the 14 factors compared between the two stocks.

Tactile Systems Technology (NASDAQ:TCMD) and NuVasive (NASDAQ:NUVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Tactile Systems Technology and NuVasive, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tactile Systems Technology01202.67
NuVasive27702.31

Tactile Systems Technology presently has a consensus price target of $59.00, indicating a potential upside of 4.76%. NuVasive has a consensus price target of $64.8667, indicating a potential downside of 5.70%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, equities analysts clearly believe Tactile Systems Technology is more favorable than NuVasive.

Earnings & Valuation

This table compares Tactile Systems Technology and NuVasive's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tactile Systems Technology$189.49 million5.84$10.97 million$0.56100.71
NuVasive$1.17 billion3.03$65.23 million$2.4727.91

NuVasive has higher revenue and earnings than Tactile Systems Technology. NuVasive is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Tactile Systems Technology has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500. Comparatively, NuVasive has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.

Profitability

This table compares Tactile Systems Technology and NuVasive's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tactile Systems Technology-4.57%1.37%0.99%
NuVasive-0.84%8.00%3.06%

Summary

NuVasive beats Tactile Systems Technology on 7 of the 12 factors compared between the two stocks.

Merit Medical Systems (NASDAQ:MMSI) and Tactile Systems Technology (NASDAQ:TCMD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Merit Medical Systems and Tactile Systems Technology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Merit Medical Systems01702.88
Tactile Systems Technology01202.67

Merit Medical Systems presently has a consensus target price of $64.3750, indicating a potential upside of 4.27%. Tactile Systems Technology has a consensus target price of $59.00, indicating a potential upside of 4.76%. Given Tactile Systems Technology's higher probable upside, analysts clearly believe Tactile Systems Technology is more favorable than Merit Medical Systems.

Earnings and Valuation

This table compares Merit Medical Systems and Tactile Systems Technology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Merit Medical Systems$994.85 million3.47$5.45 million$1.4642.40
Tactile Systems Technology$189.49 million5.84$10.97 million$0.56100.71

Tactile Systems Technology has lower revenue, but higher earnings than Merit Medical Systems. Merit Medical Systems is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

99.5% of Merit Medical Systems shares are owned by institutional investors. 4.7% of Merit Medical Systems shares are owned by insiders. Comparatively, 5.3% of Tactile Systems Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

Merit Medical Systems has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.

Profitability

This table compares Merit Medical Systems and Tactile Systems Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Merit Medical Systems-3.05%9.02%4.91%
Tactile Systems Technology-4.57%1.37%0.99%

Summary

Merit Medical Systems beats Tactile Systems Technology on 9 of the 14 factors compared between the two stocks.

AtriCure (NASDAQ:ATRC) and Tactile Systems Technology (NASDAQ:TCMD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for AtriCure and Tactile Systems Technology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AtriCure00703.00
Tactile Systems Technology01202.67

AtriCure presently has a consensus target price of $67.1429, indicating a potential upside of 0.83%. Tactile Systems Technology has a consensus target price of $59.00, indicating a potential upside of 4.76%. Given Tactile Systems Technology's higher probable upside, analysts clearly believe Tactile Systems Technology is more favorable than AtriCure.

Earnings and Valuation

This table compares AtriCure and Tactile Systems Technology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AtriCure$230.81 million13.15$-35,190,000.00($1.07)-62.24
Tactile Systems Technology$189.49 million5.84$10.97 million$0.56100.71

Tactile Systems Technology has lower revenue, but higher earnings than AtriCure. AtriCure is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

94.7% of AtriCure shares are owned by institutional investors. 5.8% of AtriCure shares are owned by insiders. Comparatively, 5.3% of Tactile Systems Technology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Volatility and Risk

AtriCure has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500.

Profitability

This table compares AtriCure and Tactile Systems Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AtriCure-21.74%-14.83%-7.77%
Tactile Systems Technology-4.57%1.37%0.99%

iRhythm Technologies (NASDAQ:IRTC) and Tactile Systems Technology (NASDAQ:TCMD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for iRhythm Technologies and Tactile Systems Technology, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
iRhythm Technologies07502.42
Tactile Systems Technology01202.67

iRhythm Technologies presently has a consensus target price of $171.7692, indicating a potential upside of 88.45%. Tactile Systems Technology has a consensus target price of $59.00, indicating a potential upside of 4.76%. Given iRhythm Technologies' higher probable upside, research analysts clearly believe iRhythm Technologies is more favorable than Tactile Systems Technology.

Profitability

This table compares iRhythm Technologies and Tactile Systems Technology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
iRhythm Technologies-20.97%-28.89%-15.11%
Tactile Systems Technology-4.57%1.37%0.99%

Earnings and Valuation

This table compares iRhythm Technologies and Tactile Systems Technology's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
iRhythm Technologies$214.55 million12.41$-54,570,000.00($2.16)-42.25
Tactile Systems Technology$189.49 million5.84$10.97 million$0.56100.71

Tactile Systems Technology has lower revenue, but higher earnings than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

iRhythm Technologies has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500. Comparatively, Tactile Systems Technology has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

Summary

Tactile Systems Technology beats iRhythm Technologies on 7 of the 12 factors compared between the two stocks.


Tactile Systems Technology Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Glaukos logo
GKOS
Glaukos
0.9$84.88+2.3%$3.80 billion$236.98 million-51.44Analyst Upgrade
Analyst Revision
Cantel Medical logo
CMD
Cantel Medical
1.3$85.38+0.5%$3.59 billion$1.02 billion101.64
NuVasive logo
NUVA
NuVasive
1.1$68.93+0.6%$3.52 billion$1.17 billion-313.32
Merit Medical Systems logo
MMSI
Merit Medical Systems
1.5$61.90+1.5%$3.39 billion$994.85 million-116.79
AtriCure logo
ATRC
AtriCure
1.5$66.60+1.0%$3.01 billion$230.81 million-57.91Analyst Report
iRhythm Technologies logo
IRTC
iRhythm Technologies
1.5$91.27+6.1%$2.50 billion$214.55 million-47.79Analyst Report
Unusual Options Activity
Analyst Revision
News Coverage
Axonics Modulation Technologies logo
AXNX
Axonics Modulation Technologies
1.3$59.36+1.4%$2.43 billion$13.82 million-30.29
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$9.10+4.1%$1.82 billion$4.11 million-6.69
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99+0.0%$1.75 billion$88.02 million-58.51Increase in Short Interest
Luminex logo
LMNX
Luminex
1.5$36.86+0.2%$1.75 billion$334.64 million94.52Analyst Upgrade
Unusual Options Activity
News Coverage
Silk Road Medical logo
SILK
Silk Road Medical
1.1$51.30+2.5%$1.72 billion$63.35 million-42.05
Alphatec logo
ATEC
Alphatec
0.8$17.20+0.4%$1.63 billion$113.43 million-15.64Insider Selling
Pulmonx logo
LUNG
Pulmonx
1.4$43.90+2.5%$1.61 billion$32.60 million0.00Increase in Short Interest
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$37.69+3.1%$1.47 billion$236.54 million-57.11
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.22+1.5%$1.38 billion$299.26 million-13.00
Atrion logo
ATRI
Atrion
1.1$647.72+0.4%$1.18 billion$155.07 million36.49
SI-BONE logo
SIBN
SI-BONE
1.2$33.15+0.5%$1.08 billion$67.30 million-20.72Increase in Short Interest
Cerus logo
CERS
Cerus
1.5$6.34+1.3%$1.05 billion$74.65 million-16.26News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$49.69+0.6%$1.03 billion$117.23 million53.43
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.61+1.1%$964.42 million$72.55 million-34.45
AngioDynamics logo
ANGO
AngioDynamics
1.4$24.00+0.1%$916.43 million$264.16 million-5.37Decrease in Short Interest
CryoLife logo
CRY
CryoLife
1.8$22.70+0.4%$891.15 million$276.22 million-59.74
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$43.12+0.8%$847.99 million$459.95 million35.93
Surmodics logo
SRDX
Surmodics
1.3$56.96+0.9%$790.83 million$94.86 million712.00
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.30+0.2%$742.48 million$154.60 million-44.78
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.03+0.2%$679.37 million$123.86 million67.18
Intersect ENT logo
XENT
Intersect ENT
1.4$19.94+1.0%$652.07 million$109.14 million-10.44
Vapotherm logo
VAPO
Vapotherm
1.5$23.03+0.2%$595.63 million$48.10 million-10.97
SeaSpine logo
SPNE
SeaSpine
1.3$21.55+2.0%$589.95 million$159.08 million-12.90Analyst Upgrade
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$41.06+1.6%$579.22 million$114.51 million-87.36Gap Down
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$21.98+2.9%$556.70 millionN/A-9.68
Accuray logo
ARAY
Accuray
2.3$5.26+0.8%$484.93 million$382.93 million37.57News Coverage
iCAD logo
ICAD
iCAD
1.5$18.46+2.0%$451.02 million$31.34 million-19.43
AVITA Medical logo
RCEL
AVITA Medical
1.5$20.89+0.6%$449.02 million$14.26 million-10.09Analyst Report
Increase in Short Interest
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$20.91+3.8%$415.73 million$11.22 million-47.52News Coverage
Profound Medical logo
PROF
Profound Medical
1.6$20.20+1.2%$414.73 million$4.17 million-17.26News Coverage
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.05+2.2%$400.19 million$24.95 million-27.42
PAVmed logo
PAVM
PAVmed
1.4$4.97+4.2%$392.51 millionN/A-6.54Gap Down
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.50+0.4%$370.59 million$198.38 million24.75
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.29+0.9%$370.01 million$2.84 million0.00News Coverage
Soliton logo
SOLY
Soliton
1.1$17.45+4.7%$352.56 millionN/A-23.27
Neuronetics logo
STIM
Neuronetics
1.5$13.15+3.3%$322.94 million$62.66 million-7.83
Apyx Medical logo
APYX
Apyx Medical
1.0$9.51+1.4%$321.90 million$28.15 million-20.23Gap Down
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$88.57+1.5%$317.93 million$46.90 million27.94
IRadimed logo
IRMD
IRadimed
1.5$23.94+2.2%$301.25 million$38.52 million74.81News Coverage
Gap Up
DarioHealth logo
DRIO
DarioHealth
1.3$18.59+0.1%$285.89 million$7.56 million-2.32
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.75+2.2%$273.47 million$220,000.0012.04
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.40+1.4%$204.92 million$8.34 million-2.03
TELA Bio logo
TELA
TELA Bio
2.1$13.90+2.2%$200.72 million$15.45 million-4.78
Titan Medical logo
TMDI
Titan Medical
1.2$1.73+1.7%$186.19 millionN/A173.00Analyst Report
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.